Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib

Amir Noeparast(Vrije Universiteit Brussel), Jacques De Grève(Vrije Universiteit Brussel)
Oncotarget
August 26, 2016
Cited by 100


Related Papers